Introduction {#Sec1}
============

The main molecular mechanism of non-β-lactamase resistance among β-lactamase-negative ampicillin-resistant (BLNAR) strains is assumed to be a decreased affinity of penicillin-binding protein (PBP)3 to β-lactams \[[@CR1]--[@CR3]\]. Ubukata et al. proved that amino acid substitutions in the SSN motifs (M377I, S385T, and L389F) and KTG motifs (R517H and N526K) in BLNAR strains are major causes of resistance to ampicillin (ABPC), and that these SNPs lead to changes in the three-dimensional structure of the active binding site of PBP3 \[[@CR4]\].

To date, along with the widespread global incidence of BLNAR *H. influenzae*, several isolates have been found to harbor the typical mutation patterns of BLNAR mutants (genotype BLNAR, gBLNAR) with susceptibility to low ABPC minimum inhibitory concentrations (MICs) \[[@CR5], [@CR6]\]. Osaki et al. reported elevated cephalosporin MICs in a strain of *H. influenzae* possessing artificially mutated *ftsI* genes, which was expected; however, the ABPC MICs were not elevated, contrary to expectations \[[@CR7]\]. These data also suggest that the *ftsI* gene could play a different role in penicillin resistance from its role in resistance to other cephalosporin antibiotics, and that resistance to ABPC is not only determined by the presence or absence of mutations on the *ftsI* gene.

Few studies have investigated the recent trends of genetic polymorphisms in the *ftsI* gene, despite the worldwide spread of BLNAR *H. influenzae*. We hypothesized that novel SNPs on the *ftsI* gene that affect the susceptibility to β-lactams have emerged and could become a threat to the world in the future. The objectives of this study were to perform comprehensive genetic analyses of whole regions of the PBPs in *H. influenzae* and to identify new SNPs related to antibiotic resistance, especially to ABPC and other cephalosporins.

Main text {#Sec2}
=========

Materials and methods {#Sec3}
---------------------

We collected 39 clinical isolates of *H. influenzae* from January 2014 to March 2016 at the National Defense Medical College Hospital. These isolates were identified using standard microbiological methods to identify *H. influenzae* (rabbit blood agar and conventional X and V factor requirements test) (Eiken Chemical Co., Tokyo, Japan, Cat. No. E-DC08) \[[@CR8]\]. Isolates were stored at − 30 °C until use and recovered after inoculation onto chocolate agar (Kyokuto Pharmaceuticals, Tokyo, Japan, Cat. No. 251169) at 37 °C in 5% CO~2~ for 24 h. Genomic DNA was extracted with the EZ Extract for DNA kit (Advanced Microorganism Research, Gifu, Japan, Cat. No. 76815M). MICs of the antibiotics were determined by the broth dilution method (Kyokuto Pharmaceuticals, Cat. Nos. 551-0000-0 and 08930), in accordance with the guidelines of the Clinical Laboratory Standard Institute (document M100-S25) \[[@CR9]\]. β-Lactamase production was identified using the nitrocefin method with BBL Cefinase Paper Disc kit (Becton--Dickinson, Franklin Lakes, NJ, Cat. No. 231650).

Extracted DNA specimens subsequently underwent library preparation using TruSeq Nano DNA Sample Preparation Kit (Illumina, San Diego, CA, Cat. Nos. FC-121-4001 and 4002), according to the low sample protocol provided. Single sequencing was performed with an Illumina HiSeq 2500 (Illumina) using 100 bp paired-end runs (Illumina, Cat. Nos. PE-401-3001, FC-401-3001 and FC-121-1003). BWA (v 0.7.15) was used to map raw FASTQ data \[[@CR10]\]. The reference sequences used in this study are listed in Additional file [1](#MOESM1){ref-type="media"}. Sequences of 16S ribosomal RNA (rRNA), *recA*, *fucK*, *hpd*, and *sodC* were used to distinguish *H. influenzae* from *H. haemolyticus* according to previous reports \[[@CR11]--[@CR14]\]. Capsular formation and serotyping were performed according to the *BexDCBA* and region II in the *cap* locus \[[@CR15]\]. Consensus FASTQ data were extracted from the mapping data, and bases with a quality score of less than 20 were eliminated. SNP detection, prediction of amino acid substitutions, and phylogenetic analyses of 16S rRNA and *recA* were performed with MEGA (v 7.0.21) \[[@CR16]\]. The presence of *fucK*, *hpd*, and *sodC* was determined from mapping data using Integrative Genomic Viewer (v 2.3.81) \[[@CR17], [@CR18]\]. All synonymous SNPs were removed in this study.

Mann--Whitney U tests were used to ascertain the association between the MICs of the antibiotics and the presence or absence of each SNP. Associations were considered statistically significant if the *p* value for any of the SNPs was less than the Bonferroni-adjusted significance threshold. All statistical analyses were calculated with R (v 3.4.0; R Foundation for Statistical Computing, Vienna, Austria \[<http://www.R-project.org/>\]) and package "EnvStats" \[[@CR19]\].

Based on the *ftsI* gene sequence information, each specimen was classified into one of the following major genotypes: β-lactamase-negative ampicillin-susceptible (gBLNAS), strains without amino acid substitutions in the KTG motif (N526K or R517H) and SSN motif (M377I, S385T, or L389F) in *ftsI*; group I BLNAR, strains with N526K in the KTG motif and no mutations in the SSN motif; group II BLNAR, strains with R517H in the KTG motif and no mutations in the SSN motif; and group III BLNAR, strains with mutations in both the SSN and the KTG motifs \[[@CR4], [@CR20]\]. In addition, we defined a strain with the *bla* gene and without amino acid substitutions in the *ftsI* gene as a β-lactamase-positive ampicillin-resistant (BLPAR) strain.

Results {#Sec4}
-------

### Origins of the clinical samples and β-lactamase producibility {#Sec5}

Among the 39 isolates, 18 were extracted from sputum and the rest from nasal discharge (15/39), bronchoalveolar lavage fluid (3/39), pharyngeal swabs (2/39), blood (2/39), and biliary drain fluid (1/39). There were 5 (12.8%) BLPAR strains, and the other 34 were non-producing strains.

### Antibiotics MICs and genotypes {#Sec6}

The MIC profiles of the antibiotics examined in this study are shown in Additional file [2](#MOESM2){ref-type="media"}. ABPC MICs were significantly higher in group III BLNAR than in the gBLNAS strains and group I/II gBLNAR strains. However, 10 of 23 specimens in group III BLNAR (43.5%) were paradoxically classified as ABPC-sensitive strains (MIC ≤ 1 µg/mL; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Relationship between non-β-lactamase-producing genotype strains and ABPC MICs. \* represents p value \< 0.05. I, II, and III represent gBLNAR groups I, II, and III respectively

### Genetic confirmation of *H. influenzae* and serotyping {#Sec7}

Genome analyses of 34 non-β-lactamase-producing strains were performed. All strains were identified as *H. influenzae* and simultaneously distinguished from both *H. parainfluenzae* and *H. haemolyticus* based on the phylogenetic analysis of 16S rRNA and *recA* genes. All 34 strains possessed the *hpd* gene; nevertheless, 2 strains were finally excluded from further SNP analysis because they lacked the *fucK* gene and had the *sodC* gene instead. The reason for their exclusion was that most *H. haemolyticus* strains possess *sodC* gene, which is a characteristic of the species, and *H. influenzae* possesses both *fucK* and *hpd* genes. The remaining 32 strains were confirmed as nontypeable serotypes because they did not have *BexDCBA* and region II in the *cap* locus.

### SNP analysis of PBP-coding genes {#Sec8}

We targeted 7 distinct genes encoding PBPs (1A, 1B, 2, 3, 4, 5, and 7) according to the NCBI information for *H. influenzae* Rd KW20 (Accession No. NC_000907). Unfortunately, we could not obtain the complete sequences of the PBP-coding genes in 5 of 32 strains, but we successfully completed SNP sequence analysis in 27. As a result of our analysis, we found SNPs with significant associations with the MICs of ABPC on the SSN motif (D350N, S357N, S385T, and L389F) and near the KTG motif (V562L) in the *ftsI* gene (coding PBP-3). Figure [2](#Fig2){ref-type="fig"} illustrates the associations between the p-values derived from Mann--Whitney U tests of non-β-lactamase-producing strains for the *ftsI* gene and the SNPs that show significant associations with the MICs of ABPC. We also found SNPs with low p-values on the SSN motif (M377I) and near the KTG motif (V562L) in the *ftsI* gene (coding PBP-3). No novel SNPs were found in the other PBP-coding genes (Fig. [2](#Fig2){ref-type="fig"}a). The MICs of the other cephalosporin antibiotics were similar to those of ABPC (Fig. [2](#Fig2){ref-type="fig"}b--f). Additionally, these SNPs showed strong positive correlations with each other (Table [1](#Tab1){ref-type="table"}).Fig. 2Association between SNPs and MICs. Plot of Mann--Whitney test p values of non-β-lactamase-producing strains. The horizontal axis shows the positions of the SNPs in each PBP coding gene. Dots represent the p values for each SNP. The upper, solid, horizontal lines show the level of significance after adjustment with the Bonferroni method (0.05 divided by 190). The two dotted lines in pbp3 represent the positions of the major SSN and KTG motif mutations: S385T and N526K. **a** ampicillin (ABPC), **b** cefaclor (CCL), **c** cefdinir (CFDN), **d** cefditoren pivoxil (CFDN-PI), **e** cefotaxime (CTX), and **f** ceftriaxone (CTRX) Table 1Correlation coefficients between 2 SNPs in the *ftsI* geneD350NS357NM377IS385TL389FV562LD350N0.9240.9240.9240.7950.739S357N0.8461.0000.8600.798M377I0.8460.8600.798S385T0.8600.798L389F0.928V562L

### Analysis of *acrA*, *acrB*, *acrR*, and *tolC* genes {#Sec9}

The sequences of *acrA, acrB, acrR,* and *tolC* genes were also analyzed in 27 samples. Whereas 16 samples had about 46 bp deletions in the *acrB* gene according to the mapping data, no significant changes in the MICs of the antibiotics were identified in either the presence or absence of the *acrB* mutations (Additional file [3](#MOESM3){ref-type="media"}).

Discussion {#Sec10}
----------

In this study, our data reconfirmed the significant associations between SNPs located in the *ftsI* gene and the MICs of ABPC or other cephalosporins in β-lactamase-negative *H. influenza*e; however, no other novel SNPs could be identified. We also found that group III BLNAR strains of *H. influenzae* with low ABPC MICs could paradoxically harbor typical SNPs in the *ftsI* gene. It was also suggested that discrepancies between the genotypes and phenotypes among BLNAR strains have already become commonplace in Japan. We identified that about up to 40% of isolates within group III gBLNAR genotype had low ABPC MICs, and these were classed as ABPC-sensitive phenotype.

We considered several reasons for the discrepancies between phenotypes and genotypes. First, MICs from the disk-testing method are considered to be influenced by the amount of bacteria in *H. influenzae* and our data reaffirmed the difficulty of predicting ABPC MICs based on the mutation pattern of the *ftsI* gene \[[@CR21]\]. Second, ABPC affinity for PBPs was different from that of the other cephalosporins. Cefotaxime and other cephalosporins have the highest affinity for PBP2, whereas ampicillin had higher affinity for PBP1A and PBP4 \[[@CR4]\]. Our data showed that cephalosporin agents tended to have a higher association with the MICs than ABPC. These findings confirm that the active sites of PBPs depend on the antibiotic agents. Third, subtle differences among clusters of species might be one of the reasons for the discrepancies between phenotypes and genotypes in clinical practice. Among the 27 isolates of *H. influenzae* identified via conventional biochemical methods, 2 were lacking the *fucK* gene and possessed the *sodC* gene instead, which is a typical profile of *H. haemolyticus* and not *H. influenzae*. Conventionally, the identification of *H. influenzae* is determined based on the results of hemolysis in rabbit blood agar and the conventional X and V factor requirements test. However, *H. haemolyticus* strains could be misdiagnosed as *H. influenzae* using these conventional protocols in clinical practice. Furthermore, even 16S rRNA phylogenetic analysis is not enough to distinguish these two species, and some of them can be categorized as "fuzzy species" \[[@CR13], [@CR14], [@CR22]--[@CR24]\]. Although β-lactamase resistance in *H. haemolyticus* is similar to that in *H. influenzae*, detailed information about mutations in the *ftsI* gene and the sensitivity of *H. haemolyticus* to ABPC and fuzzy species remains limited \[[@CR25]\].

Some reports have also suggested that efflux pumps are involved in the development of antibiotic resistance, including to ABPC \[[@CR26]--[@CR28]\]. Kaczmarek et al. indicated that both the *ftsI* and *acrR* genes are associated with the antibiotic efflux pump and frameshift mutations, especially in *acrR*, could promote high ABPC MICs by accelerating AcrAB-mediated efflux \[[@CR29]\]. However, our data did not show significant changes in the MICs either in the presence or absence of the *acrB* mutation \[[@CR30]\].

Conclusion {#Sec11}
==========

It is possible that the gBLNAR strains could spread more widely in communities than can be estimated from MIC values. Unfortunately, we could not exclude the possibility that other mechanisms independent of the SNPs could contribute to the elevations in the MICs of the antibiotics. Therefore, continuous studies are crucial in order to gain an understanding of the molecular basis of β-lactam antibiotic resistance in BLNAR *H. influenzae*. Furthermore, we should consider in detail the changes in expression that lead to antibiotic resistance in our future plans because the acquisition of resistance to antimicrobials can also be predicted by the levels of expression of a small number of genes.

Limitations {#Sec12}
===========

First, our findings demonstrated that SNPs located in the SSN motif in the *ftsI* gene correlated highly with each other and we could not conclude which of the three types of SNPs in the SSN motif contributed most to the MICs of the antibiotics. Furthermore, we cannot rule out the possibility that horizontal transfer of a resistance gene could be involved \[[@CR31]\]. Second, variations among the mutations were limited due to the small number of samples. Third, β-lactamase-positive amoxicillin/clavulanate resistant strains of *H. influenzae* have recently emerged in clinical settings \[[@CR32]\]. However, we did not include these strains because only a few were found in this study.
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